ALACHUA, Fla. (Jan. 31, 2012) – RTI Biologics Inc. (RTI) (Nasdaq: RTIX), a leading provider of orthopedic and other biologic implants, reported operating results for the fourth quarter and full year of 2011 as follows:

Quarterly Highlights:

• Achieved quarterly revenues of $42.9 million.
• Achieved quarterly net income of $2.4 million, or $0.04 per fully diluted share.
• Achieved quarterly revenues of $14.2 million in the U.S. direct distribution organization, an 11 percent increase over the fourth quarter of 2010. The U.S. direct distribution organization includes sports medicine and some bone graft substitute/general orthopedic (BGS/GO) implants.

2011 Full Year Highlights:

• Achieved record annual revenues of $169.3 million.
• Achieved annual net income of $8.4 million, or $0.15 per fully diluted share.
• Achieved annual revenues of $51.4 million in the U.S. direct distribution organization, a 10 percent increase over 2010.
• Achieved annual revenue growth in every business as reported with the exception of the dental business line. The decrease in reported dental revenues is the result of the change in the terms of the dental distributor agreement, which was announced in the third quarter of 2010. If the new terms with our distributor had been effective for the full year of 2010, and excluding dental stocking orders related to the agreement, dental revenues would have increased by 11 percent compared to the full year of 2010.
• Launched or released for distribution 18 new products or product enhancements over the year, which accounted for more than $4 million of revenue for the year.
• Achieved operating cash flow of $27.8 million.

“We are very pleased with our fourth quarter results, which ended a strong year of execution for RTI,” said Brian K. Hutchison, president and chief executive officer of RTI. “Despite the challenging economic environment in 2011, we saw growth in all of our business lines while significantly increasing cash flow, decreasing inventories and improving gross margins each quarter.”

Fourth Quarter 2011

Worldwide revenues of $42.9 million for the fourth quarter of 2011 were down 5 percent, on an as reported basis, compared to the fourth quarter of 2010, but were up 2 percent excluding dental stocking orders in the fourth quarter of 2010 as a result of the new agreement with the company’s dental distributor. Domestic revenues of $37.8 million for the fourth quarter of 2011 were down 8 percent compared to the fourth quarter of 2010. Excluding the dental stocking orders from the company’s dental distributor in the fourth quarter of 2010, domestic revenues would have been comparable to the fourth quarter of 2010, primarily based on the strength of the sports medicine and BGS/GO businesses. International revenues of $5.1 million increased 20 percent compared to the fourth quarter of 2010 due to the strength of the international dental business, along with increased volume of surgical specialties, BGS/GO and sports medicine implants into certain countries. On a constant currency basis, international revenues increased 21 percent compared to the fourth quarter of 2010.

For the fourth quarter of 2011, the company reported net income of $2.4 million and net income per fully diluted share of $0.04, based on 55.7 million fully diluted shares outstanding, compared to net income of $2.8 million and net income per fully diluted share of $0.05 based on 54.9 million fully diluted shares outstanding. Fourth quarter 2010 net income per share was favorably impacted by approximately $0.01 due to recognition of the full 2010 research and experimentation tax credit in the quarter.

Full Year 2011

Worldwide revenues of $169.3 million for the full year of 2011 were up 2 percent compared to 2010, on an as reported basis, but were up 10 percent if the new terms with the company’s dental distributor had been in effect for the full year of 2010 and excluding the related dental stocking orders. Domestic revenues of $148.3 million for the full year of 2011 were comparable to 2010. If the new terms with the company’s dental distributor had been effective for the full year of 2010 and excluding the related dental stocking orders, domestic revenues would have increased 9 percent, primarily based on the strength of the sports medicine, spine, surgical specialties and BGS/GO businesses. International revenues of $21 million for the full year of 2011 increased 15 percent, compared to 2010, primarily on the strength of the international dental and surgical specialties businesses. On a constant currency basis, international revenues increased 10 percent for the full year of 2011 compared to 2010.

For the full year of 2011, the company reported net income of $8.4 million and net income per fully diluted share of $0.15, based on 55.4 million fully diluted shares outstanding, compared to a net loss of $129 million and a net loss per fully diluted share of $2.36 based on 54.7 million fully diluted shares outstanding. Full year 2011 results were favorably impacted by approximately $0.01 due to the de-recognition of an uncertain tax liability as a result of Internal Revenue Service guidance provided during the third quarter of 2011 and applicable to the deductibility of transaction fees incurred as part of the Tutogen merger in 2008. Full year 2010 results included a decrease in net income of $134.7 million, or $2.46 per fully diluted share, due to a goodwill impairment charge in the third quarter of 2010.

Fiscal 2012 and First Quarter Outlook

The company expects full year revenues for 2012 to be between $174 million and $176 million. Full year net income per fully diluted share is expected to be in the range of $0.15 to $0.17, based on 55.8 million fully diluted shares outstanding.

For the first quarter of 2012, the company expects revenues to be between $41 million and $42 million, and net income per fully diluted share to be approximately $0.03.

“We expect that revenues in 2012 will be driven by continued growth in our direct distribution and international groups,” Hutchison said. “We anticipate growth rates at or above the market in all areas of our business. Over the course of 2012, we will be increasing our investment in new product development initiatives that we anticipate will accelerate our future revenue growth.”

Conference Call

RTI will host a conference call and simultaneous audio webcast to discuss the fourth quarter results at 8:30 a.m. ET today. The conference call can be accessed by dialing (877) 383-7419. The webcast can be accessed through the investor section of RTI’s website at www.rtix.com. A replay of the conference call will be available on the RTI website for one month following the call.

About RTI Biologics Inc.

RTI Biologics Inc. is a leading provider of sterile biologic implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening and using proprietary processes. These allograft and xenograft implants are used in orthopedic, dental and other specialty surgeries.

RTI’s innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. Two such processes – the BioCleanse® Tissue Sterilization Process and the Tutoplast® Tissue Sterilization Process – have a combined record of millions of implants distributed with zero incidence of allograft-associated infection. These processes have been validated by tissue type to inactivate or remove viruses, bacteria, fungi and spores from the tissue while maintaining biocompatibility and functionality.

RTI’s worldwide corporate headquarters are located in Alachua, Fla., with international locations in Germany and France. The company is accredited by the American Association of Tissue Banks in the United States and is a member of AdvaMed.

Forward Looking Statement

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company’s SEC filings may be obtained by contacting the company or the SEC or by visiting RTI’s website at www.rtix.com or the SEC’s website at www.sec.gov.
 

Use of Non-GAAP Financial Measures

To supplement RTI Biologic’s condensed consolidated financial statements presented on a GAAP basis, the company discloses certain non- GAAP financial measures that exclude certain amounts, including non-GAAP net income and non –GAAP net income per fully diluted share. These non-GAAP financial measures are not in accordance with, or an alternative for, generally accepted accounting principles in the United States. Reconciliations of each of these non-GAAP financial measures to the corresponding GAAP measures are included in the reconciliation above.

The following is an explanation of the adjustment that management excluded as part of the non-GAAP measures for the year ended December 31, 2010 as well as the reasons for excluding the individual item:

Goodwill impairment – This adjustment represents the write-off of remaining goodwill created through a purchase transaction. Management removes the impact of the goodwill impairment charge from the company’s operating results to assist in assessing its operating performance in the current period and to supplement a comparison to the company’s past operating performance.

Material Limitations Associated with the Use of Non-GAAP Financial Measures

Non-GAAP net income and non-GAAP net income per fully diluted share should not be considered in isolation, or as a replacement for GAAP measures.

Usefulness of Non-GAAP Financial Measures to Investors

The company believes that presenting non-GAAP net income and non-GAAP net income per fully diluted share in addition to the related GAAP measures provide investors greater transparency to the information used by management in its financial decision-making, which excludes the goodwill impairment. The company further believes that providing this information better enables RTI Biologic’s investors to understand the company’s overall core performance and to evaluate the methodology used by management to assess and measure such performance.

RTI will host a conference call and simultaneous audio webcast to discuss the fourth quarter results at 8:30 a.m. ET the same day. The conference call can be accessed by dialing (877) 383-7419. The webcast can be accessed through the investor section of RTI’s website at www.rtix.com. A replay of the conference call will be available on the RTI website for one month following the call.

About RTI Biologics Inc.

RTI Biologics Inc. is a leading provider of sterile biologic implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening, precision shaping and using proprietary, validated processes. These allograft and xenograft implants are used in orthopedic, dental and other specialty surgeries.

RTI’s innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. Two such processes – the BioCleanse® Tissue Sterilization Process and the Tutoplast® Tissue Sterilization Process – have a combined record of millions of implants distributed with zero incidence of allograft-associated infection. These processes have been validated by tissue type to inactivate or remove viruses, bacteria, fungi and spores from the tissue while maintaining biocompatibility and functionality.

RTI’s worldwide corporate headquarters are located in Alachua, Fla., with international locations in Germany and France. The company is accredited by the American Association of Tissue Banks in the United States and is a member of AdvaMed.

Forward Looking Statement

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company’s SEC filings may be obtained by contacting the company or the SEC or by visiting RTI’s website at www.rtix.com or the SEC’s website at www.sec.gov.

###

ALACHUA, Fla. (Jan. 10, 2012) – RTI Biologics Inc. (RTI) (Nasdaq: RTIX), a leading provider of orthopedic and other biologic implants, has launched an informational website to educate patients and the general public about allograft tissue. AllograftInfo.com explores the use of allograft, or human donated tissue, in surgery, as well as provides links to relevant research and articles. The website also addresses several frequently asked questions and provides suggestions on what to ask your surgeon when considering allograft.

“ AllograftInfo.com is a website we created based on surgeon feedback to provide patients a convenient and easy-to-understand portal for self-education on allograft tissue,” said Brian K. Hutchison, president and chief executive officer. “RTI believes in the life-changing benefits of allograft implants, and we hope this website helps the public and potential patients better understand allograft tissue as an available option in a variety of surgeries.”

An allograft is tissue surgically transplanted from one person to another. Most allograft tissue is recovered surgically after death; the donor must have consented to the donation before death or the donor’s family must consent after death. Allografts have been used successfully for more than 150 years, and approximately one million allografts are transplanted each year in the United States in procedures that include ACL repair, joint reconstruction in the knee and ankle, meniscal replacement, reconstruction due to cancer or trauma, ridge augmentation in dental procedures, shoulder repair, spinal fusion and urological procedures.

Allografts are used as an alternative to synthetic and metal implants. However, unlike synthetic or metal implants, allografts are natural and biocompatible scaffolds, allowing the recipient’s body to remodel it into his or her own tissue over time. Using allograft tissue rather than an autograft – or tissue from one’s own body – eliminates a second surgical site, allowing the recipient to avoid additional pain, risk and a possible longer hospital stay.

RTI honors the gift of tissue donation by treating the tissue with respect, by finding new ways to use the tissue to help patients and by helping as many patients as possible from each donation.

About RTI Biologics

RTI Biologics Inc. is a leading provider of sterile biologic implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening and using proprietary processes. These allograft and xenograft implants are used in orthopedic, dental and other specialty surgeries.

RTI’s innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. Two such processes – the BioCleanse® Tissue Sterilization Process and the Tutoplast® Tissue Sterilization Process – have a combined record of millions of implants distributed with zero incidence of allograft-associated infection. These processes have been validated by tissue type to inactivate or remove viruses, bacteria, fungi and spores from the tissue while maintaining biocompatibility and functionality.

RTI’s worldwide corporate headquarters are located in Alachua, Fla., with international locations in Germany and France. The company is accredited by the American Association of Tissue Banks in the United States and is a member of AdvaMed.

In 2007, the RTI facilities team began transitioning to a condition-based maintenance program in the company’s 65,000 sq. ft. processing facility. The program combines skilled and trained personnel, specific predictive maintenance tools and equipment, and analysis of data such as vibration analysis, oil quality, thermal and infrared readings from the facility equipment. Using this data, the facilities team can predict when equipment failure might occur and therefore, equipment can be repaired at convenient times that will minimize work flow disruptions. Since the implementation of the program, the equipment performance rating for RTI went from 80 percent to 98.7 percent over four years, placing RTI among the top echelons of facilities in the U.S.

In 2010, RTI was the first U.S.-based company to implement an advanced vibration-detection technology to monitor the health of its machinery. RTI was selected for the initial implementation honor by SKF, developer of the technology, based on the work the company had already been doing to move to a condition-based maintenance program. The SKF machinery health reporting system allows the RTI facilities team to track machinery performance issues more accurately, trend patterns farther in advance and sustain high machinery performance levels.

“The investment of time and resources into condition-based maintenance has been very important to RTI,” said Chuck Ratliff, RTI director of facilities. “Because of the intricacy of our processes and the importance of protecting donor tissue it is critical that our equipment be reliable and accurate.”

“We are very proud of our facilities team for achieving such high standards in equipment maintenance,” said Thomas F. Rose, RTI executive vice president and chief operations officer. “Our facility is unlike most others, in that our technicians are preparing human donated tissue for transplantation for recipients around the country. Most companies cannot afford the disruption in work flow that equipment failures bring, but when your company is the crucial step between tissue donation and transplantation, you have additional responsibility for ensuring your equipment is always in top condition.”

About RTI Biologics
RTI Biologics Inc. is a leading provider of sterile biologic implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening and using proprietary processes. These allograft and xenograft implants are used in orthopedic, dental and other specialty surgeries.

RTI’s innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. Two such processes – the BioCleanse® Tissue Sterilization Process and the Tutoplast® Tissue Sterilization Process – have a combined record of millions of implants distributed with zero incidence of allograft-associated infection. These processes have been validated by tissue type to inactivate or remove viruses, bacteria, fungi and spores from the tissue while maintaining biocompatibility and functionality.

RTI’s worldwide corporate headquarters are located in Alachua, Fla., with international locations in Germany and France. The company is accredited by the American Association of Tissue Banks in the United States and is a member of AdvaMed.

About SKF Group and Evolution
SKF Group is a leading global supplier of bearings, seals, mechatronics, lubrication systems, and services include technical support, maintenance and reliability services, engineering consulting and training. SKF is represented in more than 130 countries and has 15,000 distributor locations worldwide.

Evolution is a business and technology magazine issued by SKF. The print version is published four times a year in 12 editions – U.S. and British English, Chinese, Czech, French, German, Hungarian, Italian, Polish, Russian, Spanish and Swedish.

The online version of Evolution is published in eight editions – U.S. and British English, French, German, Italian, Russian, Spanish and Swedish.

As a company, RTI is committed to making a positive impact through its activities with employees, communities, the environment and all stakeholders. This report is a true testament to all RTI employees’ hard work and commitment. Not only does RTI want to provide safe, quality implants to patients and surgeons around the world but to do so in a responsible manner.

See RTI’s corporate social responsibility report here: http://www.rtix.com/about/corporate-social-responsibility/.

About RTI Biologics Inc.
RTI Biologics Inc. is a leading provider of sterile biologic implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening and using proprietary processes. These allograft and xenograft implants are used in orthopedic, dental and other specialty surgeries.

RTI’s innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. Two such processes – the BioCleanse® Tissue Sterilization Process and the Tutoplast® Tissue Sterilization Process – have a combined record of more than two million implants distributed with zero incidence of allograft-associated infection. These processes have been validated by tissue type to inactivate or remove viruses, bacteria, fungi and spores from the tissue while maintaining biocompatibility and functionality.

RTI’s worldwide corporate headquarters are located in Alachua, Fla., with international locations in Germany and France. The company is accredited by the American Association of Tissue Banks in the United States and is a member of AdvaMed.

ALACHUA, Fla. (Oct. 27, 2011) – RTI Biologics Inc. (RTI) (Nasdaq: RTIX), a leading provider of orthopedic and other biologic implants, reported operating results for the third quarter of 2011 as follows:

Quarterly Highlights:

• Achieved quarterly revenues of $42.3 million.
• Achieved quarterly net income of $2.7 million, or $0.05 per fully diluted share.
• Achieved quarterly revenues of $12.1 million in the U.S. direct distribution organization, a 7 percent increase over the third quarter of 2010. The U.S. direct distribution organization includes sports medicine and some bone graft substitute/general orthopedic (BGS/GO) implants.
• Achieved quarterly revenues of $7.5 million in the surgical specialties business, an 11 percent increase over third quarter 2010.
• Achieved quarterly revenues of $7.0 million in the BGS/GO business, a 24 percent increase over third quarter 2010.
• Achieved international revenues of $5.0 million, an 18 percent increase over the third quarter of 2010.
• Released one new spinal construct, one BGS/GO implant and one surgical specialties implant for distribution with three different commercial distributors.
• “We are pleased with our third quarter results, which exceeded our expectations and were driven primarily by growth in surgical specialties and BGS/GO,” said Brian K. Hutchison, chief executive officer of RTI. “The decrease in reported dental revenues is the result of the change in the terms of our distributor agreement, which was announced in the third quarter of 2010. If the new terms with our distributor had been effective for the entire third quarter of 2010, dental revenues would have increased by 17 percent compared to the third quarter of 2010.”

Worldwide revenues of $42.3 million for the third quarter of 2011 were up 1 percent compared to the third quarter of 2010. Domestic revenues of $37.3 million for the third quarter of 2011 were comparable to the third quarter of 2010. If the new terms with the company’s dental distributor had been effective for the entire third quarter of 2010, domestic revenues would have increased by 9 percent compared to the third quarter of 2010, primarily based on the strength of the dental, surgical specialties and BGS/GO businesses. International revenues of $5.0 million increased 18 percent due to growth in all businesses from the company’s international operations in Germany, offset by declines in revenues from exports to other countries. On a constant currency basis, international revenues increased 9 percent compared to the third quarter of 2010.

For the third quarter of 2011, the company reported net income of $2.7 million and net income per fully diluted share of $0.05, based on 55.4 million fully diluted shares outstanding, compared to a net loss of $133.1 million and a net loss per fully diluted share of $2.43 based on 54.8 million fully diluted shares outstanding. Third quarter 2011 earnings per share were favorably impacted by approximately $0.01 due to the de-recognition of an uncertain tax liability as a result of Internal Revenue Service guidance provided during the third quarter of 2011 and applicable to the deductibility of transaction fees incurred as part of the Tutogen merger in 2008. Third quarter 2010 results included a decrease in net income of $134.7 million, or $2.46 per fully diluted share, due to a goodwill impairment charge.

Fiscal 2011 and Fourth Quarter Outlook

As a result of better than expected results through the first nine months of the year, the company is raising its full year revenue guidance for 2011. The company now expects full year revenues for 2011 to be between $166 million and $167 million, as compared to prior guidance of between $164 million and $166 million. Full year net income is expected to be approximately $0.14 per fully diluted share, based on 55.4 million shares outstanding, at the top end of our prior guidance of between $0.12 and $0.14 per fully diluted share.

For the fourth quarter of 2011, the company expects revenues to be between $40 million and $41 million, and net income per fully diluted share to be approximately $0.03.

“Despite the challenging economic environment, we are pleased with our progress in the first three quarters of 2011.” Hutchison said. “We are raising on our annual revenue guidance based on stronger than expected results through the first three quarters of 2011 and visibility into fourth quarter orders.”

Conference Call

RTI will host a conference call and simultaneous audio webcast to discuss the third quarter results at 8:30 a.m. ET today. The conference call can be accessed by dialing (877) 383-7419. The webcast can be accessed through the investor section of RTI’s website at www.rtix.com. A replay of the webcast will be available on the RTI website following the call.

About RTI Biologics Inc.

RTI Biologics Inc. is a leading provider of sterile biologic implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening and using proprietary processes. These allograft and xenograft implants are used in orthopedic, dental and other specialty surgeries.

RTI’s innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. Two such processes – the BioCleanse® Tissue Sterilization Process and the Tutoplast® Tissue Sterilization Process – have a combined record of millions of implants distributed with zero incidence of allograft-associated infection. These processes have been validated by tissue type to inactivate or remove viruses, bacteria, fungi and spores from the tissue while maintaining biocompatibility and functionality.

RTI’s worldwide corporate headquarters are located in Alachua, Fla., with international locations in Germany and France. The company is accredited by the American Association of Tissue Banks in the United States and is a member of AdvaMed.

Forward Looking Statement

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company’s SEC filings may be obtained by contacting the company or the SEC or by visiting RTI’s website at www.rtix.com or the SEC’s website at www.sec.gov.

To view the XBRL filing, please click here.

Use of Non-GAAP Financial Measures

To supplement RTI Biologic’s condensed consolidated financial statements presented on a GAAP basis, the company discloses certain non- GAAP financial measures that exclude certain amounts, including non-GAAP net income and non –GAAP net income per fully diluted share. These non-GAAP financial measures are not in accordance with, or an alternative for, generally accepted accounting principles in the United States. Reconciliations of each of these non-GAAP financial measures to the corresponding GAAP measures are included in the reconciliation above.

The following is an explanation of the adjustment that management excluded as part of the non-GAAP measures for the three and nine month periods ended September 30, 2010 as well as the reasons for excluding the individual item:

Impairment charges – These adjustments represent one-time charges and relate to evaluating the goodwill that has been created through purchase transactions. Management removes the impact of the goodwill impairment charge from the Company’s operating results to assist in assessing its operating performance in the current period and to supplement a comparison to the Company’s past operating performance.

Material Limitations Associated with the Use of Non-GAAP Financial Measures

Non-GAAP net income and non-GAAP net income per fully diluted share should not be considered in isolation, or as a replacement for GAAP measures.

Usefulness of Non-GAAP Financial Measures to Investors

The Company believes that presenting non-GAAP net income and non-GAAP net income per fully diluted share in addition to the related GAAP measures provide investors greater transparency to the information used by management in its financial decision-making which excludes the impairment charges. The Company further believes that providing this information better enables RTI Biologic’s investors to understand the Company’s overall core performance and to evaluate the methodology used by management to assess and measure such performance.

RTI will host a conference call and simultaneous audio webcast to discuss the third quarter results at 8:30 a.m. ET the same day. The conference call can be accessed by dialing (877) 383-7419. The webcast can be accessed through the investor section of RTI’s website at www.rtix.com

About RTI Biologics Inc.

RTI Biologics Inc. is a leading provider of sterile biologic implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening, precision shaping and using proprietary, validated processes. These allograft and xenograft implants are used in orthopedic, dental and other specialty surgeries.
RTI’s innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. Two such processes – the BioCleanse® Tissue Sterilization Process and the Tutoplast® Tissue Sterilization Process – have a combined record of millions of implants distributed with zero incidence of allograft-associated infection. These processes have been validated by tissue type to inactivate or remove viruses, bacteria, fungi and spores from the tissue while maintaining biocompatibility and functionality.
RTI’s worldwide corporate headquarters are located in Alachua, Fla., with international locations in Germany and France. The company is accredited by the American Association of Tissue Banks in the United States and is a member of AdvaMed.

Forward Looking Statement

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company’s SEC filings may be obtained by contacting the company or the SEC or by visiting RTI’s website at www.rtix.com or the SEC’s website at www.sec.gov.

The Tutoplast process is a chemical sterilization methodology originally developed by Tutogen Medical, GmbH in Neunkirchen, Germany, which merged with RTI in February 2008, to sterilize and preserve tissue for implantation. Membrane and soft tissue augmentation grafts, as well as bone particulate, sterilized through Tutoplast are used in dental, urological and other procedures.

“We are extremely proud of our clinical history of Tutoplast-sterilized implants, a track record that is unmatched in the industry today in terms of longevity,” said Robby Lane, General Manager of Tutogen Medical, GmbH. “Patient safety is a top priority for our company, and proven sterilization of biologic tissue allows us to provide safe human and animal tissue for use in a variety of surgeries.”

About Tutogen Medical, GmbH

Tutogen Medical, GmbH is RTI Biologics’ German subsidiary that processes allograft and xenograft implants for global distribution. Tutogen Medical has more than 40 years of experience in providing safe, high quality biologic implants for surgeons and their patients worldwide.

About RTI Biologics Inc.

RTI Biologics Inc. is a leading provider of sterile biologic implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening and using proprietary processes. These allograft and xenograft implants are used in orthopedic, dental and other specialty surgeries.

RTI’s innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. Two such processes – the BioCleanse® Tissue Sterilization Process and the Tutoplast® Tissue Sterilization Process – have a combined record of more than two million implants distributed with zero incidence of allograft-associated infection. These processes have been validated by tissue type to inactivate or remove viruses, bacteria, fungi and spores from the tissue while maintaining biocompatibility and functionality.

RTI’s worldwide corporate headquarters are located in Alachua, Fla., with international locations in Germany and France. The company is accredited by the American Association of Tissue Banks in the United States and is a member of AdvaMed.

###

ALACHUA, Fla. (July 28, 2011) – RTI Biologics Inc. (RTI) (Nasdaq: RTIX), a leading provider of orthopedic and other biologic implants, reported operating results for the second quarter of 2011 as follows:

Quarterly Highlights:

• A chieved quarterly revenues of $43.5 million.
• Achieved quarterly net income of $2.0 million, or $0.04 per fully diluted share.
• Achieved quarterly revenues of $12.1 million in the sports medicine business, a 5 percent increase over the second quarter of 2010.
• Achieved quarterly revenues of $7.2 million in the surgical specialties business, a 21 percent increase over the second quarter of 2010.
• Achieved quarterly revenues of $12.9 million in the U.S. direct distribution organization, an 11 percent increase over the second quarter of 2010. The U.S. direct distribution organization includes sports medicine and some BGS/GO implants
• Launched BioAdapt™ DBM Foam, a flexible demineralized bone matrix (DBM) solution.
• Released two new spinal constructs and one bone graft substitute (BGS) for distribution with three different commercial distributors.

“We are pleased with our second quarter results, which exceeded our expectations and were driven primarily by continued growth in our surgical specialties and direct sports medicine businesses,” said Brian K. Hutchison, chief executive officer of RTI. “Revenues in the spine business were up slightly on a sequential quarter basis; however, it remains too early to determine if market pressures are abating. The decrease in reported dental revenues is the result of the change in the terms of our distributor agreement, which was announced in the third quarter of 2010. If the new terms with our distributor had been effective in the second quarter of 2010, dental revenues would have increased by 22 percent.”

Worldwide revenues of $43.5 million for the second quarter of 2011 increased 6 percent compared to the second quarter of 2010. Domestic revenues of $38.0 million for the second quarter of 2011 grew by 5 percent as we recognized increases in spine, surgical specialties and the direct sports medicine businesses. The domestic spine and surgical specialties businesses both benefited from a favorable quarterly comparison as a result of inventory reductions made by several of our distributors in the second quarter of 2010. International revenues of $5.5 million increased 11 percent due to a favorable foreign exchange rate in the quarter. On a constant currency basis, international revenues were comparable to the second quarter of 2010.

For the second quarter of 2011, the company reported net income of $2.0 million and net income per fully diluted share of $0.04, based on 55.3 million fully diluted shares outstanding, compared to net income of $948,000 or $0.02 per fully diluted share for the second quarter of 2010, based on 55.1 million fully diluted shares outstanding.

Fiscal 2011 and Third Quarter Outlook

As a result of first half results that exceeded expectations and better visibility into second half trends, the company is raising its full year revenue and EPS guidance for 2011. The company now expects full year revenues for 2011 to be between $164 million to $166 million, as compared to prior guidance of $159 million to $162 million. Full year net income per fully diluted share are now expected to be in the range of $0.12 to $0.14, based on 55.4 million shares outstanding, as compared to prior guidance of $0.11 to $0.13 per fully diluted share.

For the third quarter of 2011, the company expects revenues to be between $40 million to $41 million, and net income per fully diluted share to be approximately $0.03.

“We had a solid first half of the year and made progress in many key areas,” Hutchison said. “We are raising our annual guidance based on stronger than expected first half results and the expectation of continued momentum within our direct business.”

Conference Call

RTI will host a conference call and simultaneous audio webcast to discuss the second quarter results at 8:30 a.m. ET today. The conference call can be accessed by dialing (877) 383-7419. The webcast can be accessed through the investor section of RTI’s website at www.rtix.com. A replay of the conference call will be available on the RTI website following the call.

About RTI Biologics Inc.

RTI Biologics Inc. is a leading provider of sterile biologic implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening and using proprietary processes. These allograft and xenograft implants are used in orthopedic, dental and other specialty surgeries.

RTI’s innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. Two such processes – the BioCleanse® Tissue Sterilization Process and the Tutoplast® Tissue Sterilization Process – have a combined record of more than two million implants distributed with zero incidence of allograft-associated infection. These processes have been validated by tissue type to inactivate or remove viruses, bacteria, fungi and spores from the tissue while maintaining biocompatibility and functionality.

RTI’s worldwide corporate headquarters are located in Alachua, Fla., with international locations in Germany and France. The company is accredited by the American Association of Tissue Banks in the United States and is a member of AdvaMed.

Forward Looking Statement

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company’s SEC filings may be obtained by contacting the company or the SEC or by visiting RTI’s website at www.rtix.com or the SEC’s website at www.sec.gov.

To view the XBRL filing, please click here.

RTI will host a conference call and simultaneous audio webcast to discuss the second quarter results at 8:30 a.m. ET the same day. The conference call can be accessed by dialing (877) 383-7419. The webcast can be accessed through the investor section of RTI’s website at www.rtix.com. A replay of the conference call will be available on the RTI website for one month following the call.

About RTI Biologics Inc.

RTI Biologics Inc. is a leading provider of sterile biologic implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening, precision shaping and using proprietary, validated processes. These allograft and xenograft implants are used in orthopedic, dental and other specialty surgeries.

RTI’s innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. Two such processes – the BioCleanse® Tissue Sterilization Process and the Tutoplast® Tissue Sterilization Process – have a combined record of more than two million implants distributed with zero incidence of allograft-associated infection. These processes have been validated by tissue type to inactivate or remove viruses, bacteria, fungi and spores from the tissue while maintaining biocompatibility and functionality.

RTI’s worldwide corporate headquarters are located in Alachua, Fla., with international locations in Germany and France. The company is accredited by the American Association of Tissue Banks in the United States and is a member of AdvaMed.

Forward Looking Statement

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company’s SEC filings may be obtained by contacting the company or the SEC or by visiting RTI’s website at www.rtix.com or the SEC’s website at www.sec.gov.

The new instrumentation features enhancements to the design of several critical components of the set resulting from surgeon recommendations to enhance the implant procedure.

The new meniscus allograft instrumentation kits began shipping together with RTI meniscus grafts on July 5, 2011. For more information or to speak with RTI’s customer service please contact 1-800-624-7238 or visit the RTI exhibit at the American Orthopaedic Society of Sports Medicine Annual Meeting, July 7-10 in San Diego, CA.

About RTI Biologics Inc.

RTI Biologics Inc. is a leading provider of sterile biologic implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening and using proprietary processes. These allograft and xenograft implants are used in orthopedic, dental and other specialty surgeries.

RTI’s innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. Two such processes – the BioCleanse® Tissue Sterilization Process and the Tutoplast® Tissue Sterilization Process – have a combined record of more than two million implants distributed with zero incidence of allograft-associated infection. These processes have been validated by tissue type to inactivate or remove viruses, bacteria, fungi and spores from the tissue while maintaining biocompatibility and functionality.

RTI’s worldwide corporate headquarters are located in Alachua, Fla., with international locations in Germany and France. The company is accredited by the American Association of Tissue Banks in the United States and is a member of AdvaMed.

BioAdapt is the newest addition to RTI’s broad osteobiologic product portfolio. Designed to maximize ease of use, BioAdapt is a sterile, room temperature implant offered in five pre-shaped options to meet the bone grafting needs of trauma, reconstructive, spine and extremity surgeons. With foam-like properties, BioAdapt expands with hydration to adapt to the contours of the surgical site. This versatile implant offers flexible, yet cohesive handling characteristics, making it easy to shape or mold to fit various defects.

BioAdapt will be available exclusively from RTI Biologics. To learn more about BioAdapt please visit www.rtix.com or contact RTI’s customer service department at 1-800-624-7238.

About RTI Biologics Inc.

RTI Biologics Inc. is a leading provider of sterile biologic implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening and using proprietary processes. These allograft and xenograft implants are used in orthopedic, dental and other specialty surgeries.

RTI’s innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. Three such processes – the BioCleanse® Tissue Sterilization Process, the Cancelle™ SP DBM Sterilization Process and the Tutoplast® Tissue Sterilization Process – have a combined record of more than two million implants distributed with zero incidence of allograft-associated infection. These processes have been validated by tissue type to inactivate or remove viruses, bacteria, fungi and spores from the tissue while maintaining biocompatibility and functionality.

RTI’s worldwide corporate headquarters are located in Alachua, Fla., with international locations in Germany and France. The company is accredited by the American Association of Tissue Banks in the United States and is a member of AdvaMed.

Forward Looking Statement

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company’s SEC filings may be obtained by contacting the company or the SEC or by visiting RTI’s website at www.rtix.com or the SEC’s website at www.sec.gov.

ALACHUA, Fla. (May 10, 2011) – RTI Biologics Inc. (RTI) (Nasdaq: RTIX), a leading provider of orthopedic and other biologic implants, announced today that the board of directors has separated the roles of chairman of the board and chief executive officer (CEO). Dean H. Bergy assumed the role of chairman of the board of directors effective May 5, 2011, while Brian K. Hutchison remains CEO of the company and a member of the board of directors.

In conjunction with this change, the duties of the lead director have been transferred to the chairman position, and the lead director title, held by Peter F. Gearen, M.D. since July 2010, has been eliminated. Gearen remains a member of the board of directors.

“RTI has always strived to maintain high corporate governance standards, and the board has evaluated its leadership structure each year,” said Dean H. Bergy, RTI’s chairman of the board. “The board of directors decided to proactively make this change based on an evaluation of current best practices of corporate governance.”

“Dean is an exceptional executive and has deep experience with the intricacies of the healthcare and medical device industries,” said Brian K. Hutchison, RTI’s CEO. “We are very pleased he has agreed to take on the role of chairman.”

Bergy, 51, joined RTI’s Board of Directors in July 2010. His public accounting and executive management experience provides RTI’s board of directors with valuable financial reporting, compliance, and accounting and controls experience.

Bergy currently serves as advisor to the chief financial officer at Stryker, a position he has held since April 2009. He served the previous six years as Stryker’s vice president and chief financial officer. Prior to that, Bergy served as vice president of finance and chief accounting officer, vice president of finance for Stryker’s Medical Division, and started his tenure with Stryker in 1994 as the corporate controller. Previous to joining Stryker, he worked with Ernst & Young and Price Waterhouse. Bergy earned a bachelor’s degree in business administration from University of Michigan in Ann Arbor and completed the Program for Management Development from Harvard Business School.

Hutchison, 51, was named chairman and chief executive officer for RTI Biologics in February 2008. He joined RTI in December 2001 as president and CEO and was elected chairman of the board of directors in December 2002.

About RTI Biologics Inc.

RTI Biologics Inc. is a leading provider of sterile biologic implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening and using proprietary processes. These allograft and xenograft implants are used in orthopedic, dental and other specialty surgeries.

RTI’s innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. Two such processes – the BioCleanse® Tissue Sterilization Process and the Tutoplast® Tissue Sterilization Process – have a combined record of more than two million implants distributed with zero incidence of allograft-associated infection. These processes have been validated by tissue type to inactivate or remove viruses, bacteria, fungi and spores from the tissue while maintaining biocompatibility and functionality.

RTI’s worldwide corporate headquarters are located in Alachua, Fla., with international locations in Germany and France. The company is accredited by the American Association of Tissue Banks in the United States and is a member of AdvaMed.

Forward Looking Statement

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company’s SEC filings may be obtained by contacting the company or the SEC or by visiting RTI’s website at www.rtix.com or the SEC’s website at www.sec.gov.

ALACHUA, Fla. (April 28, 2011) – RTI Biologics Inc. (RTI) (Nasdaq: RTIX), a leading provider of orthopedic and other biologic implants, reported operating results for the first quarter of 2011 as follows:

Quarterly Highlights:

• Achieved quarterly revenues of $40.6 million, exceeding the company’s guidance of $38-39 million.
• Achieved quarterly net income of $1.2 million, or $0.02 per fully diluted share, in line with the company’s guidance.
• Achieved quarterly revenues of $11.7 million in the sports medicine business, a 13 percent increase over the first quarter of 2010.
• Achieved international revenue growth of 13 percent.
• Launched new version of the BTB Select and fresh stored distal tibia implants.
• Signed agreement to provide spinal allograft implants to Alphatec Spine Inc.

“We are pleased with our first quarter results, which exceeded our expectations and were driven primarily by continued growth in our surgical specialties and direct sports medicine businesses,” said Brian K. Hutchison, chairman and CEO of RTI. “Revenues in the spine business were up slightly on a sequential quarter basis; however, it is still too early to determine if market pressures are abating. The decrease in reported dental revenues is the result of the change in terms of our distributor agreement, which was announced in the third quarter of 2010. If the new terms with our distributor had been effective in the first quarter of 2010, dental revenues would have increased by 4 percent.”

Worldwide revenues of $40.6 million for the first quarter of 2011 increased 8 percent compared to the first quarter of 2010. Domestic revenues of $35.2 million for the first quarter of 2011 increased 7 percent on the strength of the spine, surgical specialties and the direct sports medicine businesses. The domestic spine and surgical specialties businesses both benefited from a favorable quarterly comparison as a result of inventory reductions made by several of our distributors in the first quarter of 2010. International revenues of $5.4 million increased 13 percent, or 14 percent on a constant currency basis, primarily due to growth in export of sports medicine and bone graft substitutes/general orthopedics, as well as growth in international dental revenues.

For the first quarter of 2011, the company reported net income of $1.2 million and net income per fully diluted share of $0.02, based on 55 million fully diluted shares outstanding, compared to net loss of $54,000 or break even per fully diluted share for the first quarter of 2010, based on 54.6 million fully diluted shares outstanding.

Fiscal 2011 and Second Quarter Outlook

As stated in RTI’s February 2011 release, the company expects full year revenues for 2011 to be between $159 million and $162 million. Full year earnings per fully diluted share are expected to be in the range of $0.11 to $0.13, based on 55.4 million fully diluted shares outstanding.

For the second quarter of 2011, the company expects revenues to be between $40 million and $41 million, and earnings per fully diluted share to be approximately $0.03.

“We had a good start to the year with solid results for the first quarter of 2011,” Hutchison said. “We are maintaining our annual guidance as we anticipate having to continue to balance effective use of incoming tissue, seasonality of surgeries and overall market pressures on our distributors.”

Conference Call

RTI will host a conference call and simultaneous audio webcast to discuss the first quarter 2011 results at 8:30 a.m. ET today. The conference call can be accessed by dialing (877) 383-7419. The webcast can be accessed through the investor section of RTI’s website at www.rtix.com. A replay of the webcast will be available on the RTI website following the call.

About RTI Biologics Inc.

RTI Biologics Inc. is a leading provider of sterile biologic implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening and using proprietary processes. These allograft and xenograft implants are used in orthopedic, dental and other specialty surgeries.

RTI’s innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. Two such processes – the BioCleanse® Tissue Sterilization Process and the Tutoplast® Tissue Sterilization Process – have a combined record of more than two million implants distributed with zero incidence of allograft-associated infection. These processes have been validated by tissue type to inactivate or remove viruses, bacteria, fungi and spores from the tissue while maintaining biocompatibility and functionality.

RTI’s worldwide corporate headquarters are located in Alachua, Fla., with international locations in Germany and France. The company is accredited by the American Association of Tissue Banks in the United States and is a member of AdvaMed.

Forward Looking Statement

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company’s SEC filings may be obtained by contacting the company or the SEC or by visiting RTI’s website at www.rtix.com or the SEC’s website at www.sec.gov.

RTI will host a conference call and simultaneous audio webcast to discuss the first quarter results at 8:30 a.m. ET the same day. The conference call can be accessed by dialing (877) 383-7419. The webcast can be accessed through the investor section of RTI’s website at www.rtix.com. A replay of the conference call will be available on the RTI website for one month following the call.

About RTI Biologics Inc.

RTI Biologics Inc. is a leading provider of sterile biologic implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening, precision shaping and using proprietary, validated processes. These allograft and xenograft implants are used in orthopedic, dental and other specialty surgeries.

RTI’s innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. Two such processes – the BioCleanse® Tissue Sterilization Process and the Tutoplast® Tissue Sterilization Process – have a combined record of more than two million implants distributed with zero incidence of allograft-associated infection. These processes have been validated by tissue type to inactivate or remove viruses, bacteria, fungi and spores from the tissue while maintaining biocompatibility and functionality.

RTI’s worldwide corporate headquarters are located in Alachua, Fla., with international locations in Germany and France. The company is accredited by the American Association of Tissue Banks in the United States and is a member of AdvaMed.

Forward Looking Statement

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company’s SEC filings may be obtained by contacting the company or the SEC or by visiting RTI’s website at www.rtix.com or the SEC’s website at www.sec.gov.

###

ALACHUA, Fla. (April 18, 2011) – RTI Biologics Inc. (RTI) (Nasdaq: RTIX), a leading provider of orthopedic and other biologic implants, announced today that it has signed an agreement to provide spinal allograft implants to Alphatec Spine, Inc.

Under the agreement, which is effective immediately and has a three year term with the option to renew, RTI will process allograft implants for use in spine made from assembled cortical allograft.

“We are pleased to work with Alphatec Spine to deliver sterile spinal implants to surgeons,” said Brian K. Hutchison, RTI’s chairman and chief executive officer. “Through our agreement, we will be able to help even more patients with biologic solutions in spine.”

“RTI has a long history of providing exceptional quality and high precision machined allografts for patients undergoing spine surgery,” said Dirk Kuyper, Alphatec Spine’s president and chief executive officer. “This relationship will allow us to continue to meet and exceed our customers’ expectations”.

About Alphatec Spine, Inc.

Alphatec Spine, Inc. is a wholly owned subsidiary of Alphatec Holdings, Inc. (Nasdaq:ATEC). Alphatec Spine is a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spine disorders, primarily focused on the aging spine. The Company’s mission is to combine world-class customer service with innovative, surgeon-driven design that will help improve the aging patient’s quality of life. The Company is poised to achieve its goal through new solutions for patients with osteoporosis, stenosis and other aging spine deformities, improved minimally invasive products and techniques and integrated biologics solutions. In addition to its U.S. operations, the Company also markets its products in over 50 international markets through its subsidiary, Scient’x S.A.S., via a direct salesforce in France, Italy and the United Kingdom and via independent distributors in the rest of Europe, the Middle East and Africa, South America and Latin America. In Asia and Australia, the Company markets its products through its subsidiary, Alphatec Pacific, Inc., and through Scient’x‘s distributors in China, Korea and Australia.

About RTI Biologics Inc.

RTI Biologics Inc. is a leading provider of sterile biologic implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening and using proprietary processes. These allograft and xenograft implants are used in orthopedic, dental and other specialty surgeries.

RTI’s innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. Two such processes – the BioCleanse® Tissue Sterilization Process and the Tutoplast® Tissue Sterilization Process – have a combined record of more than two million implants distributed with zero incidence of allograft-associated infection. These processes have been validated by tissue type to inactivate or remove viruses, bacteria, fungi and spores from the tissue while maintaining biocompatibility and functionality.

RTI’s worldwide corporate headquarters are located in Alachua, Fla., with international locations in Germany and France. The company is accredited by the American Association of Tissue Banks in the United States and is a member of AdvaMed.

Forward Looking Statement

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company’s SEC filings may be obtained by contacting the company or the SEC or by visiting RTI’s website at www.rtix.com or the SEC’s website at www.sec.gov.

ALACHUA, Fla. (Feb. 3, 2010) – RTI Biologics Inc. (RTI) (Nasdaq: RTIX), a leading provider of orthopedic and other biologic implants, reported operating results for the fourth quarter of 2010 as follows:

Quarterly Highlights:

• Achieved quarterly revenues of $45.4 million, a new record for the company.
• Achieved quarterly net income of $2.8 million, or $0.05 per fully diluted share.
• Achieved record quarterly revenues of $12.3 million in the sports medicine business.
• Achieved revenue growth in the domestic sports medicine business of 25 percent over the fourth quarter of 2009.
• Achieved revenue growth in the surgical specialties business of 29 percent over the fourth quarter of 2009.
• Launched a new bone construct and bone graft substitute to distributors.

“Revenues in the fourth quarter met expectations as our direct businesses, including sports medicine, demonstrated continued strength. Notably, we saw strong surgeon demand at the end of the year as the result of increased case volumes,” said Brian K. Hutchison, chairman and CEO of RTI. “Additionally, our continued focus on increasing operating cash flow, including inventory reductions, resulted in a strengthening of the balance sheet.”

Revenues of $45.4 million for the fourth quarter of 2010 increased 8 percent compared to the fourth quarter of 2009. Domestic revenues of $41.1 million for the fourth quarter increased 15 percent on the strength of the surgical specialties and the direct sports medicine businesses. International revenues of $4.3 million decreased 30 percent, or 25 percent on a constant currency basis, primarily due to declines in dental revenue and continued economic weakness in several international markets.

For the fourth quarter of 2010, the company reported net income of $2.8 million and net income per fully diluted share of $0.05 based on 54.9 million fully diluted shares outstanding, compared to net income of $1.5 million and net income per fully diluted share of $0.03 for the fourth quarter of 2009, based on 54.9 million fully diluted shares outstanding.

Record revenues of $166.2 million for the full year increased 1 percent compared to 2009. The company reported a net loss of $129.4 million and a net loss of $2.36 per fully diluted share for the full year. Full year results include a decrease in net income of $134.7 million, or $2.46 per fully diluted share, due to a goodwill impairment charge, as announced in the third quarter of 2010. Adjusted net income for 2010 excluding this goodwill impairment charge was $5.3 million, or $0.10 per fully diluted share.

Fiscal 2011 and First Quarter Outlook

The company expects full year revenues for 2011 to be between $159 million and $162 million. Full year earnings per fully diluted share are expected to be in the range of $0.11 to $0.13, based on 55.4 million fully diluted shares outstanding.

For the first quarter of 2011, the company expects revenues to be between $38 million and $39 million, and approximately $0.02 per fully diluted share.

“We expect that revenues in 2011 will be driven by continued growth in our direct distribution group as well as new product introductions,” Hutchison said. “While we are focused on controlling expenses, we are investing in initiatives that we anticipate will accelerate our future revenue growth and support our new product development.”

Conference Call

RTI will host a conference call and simultaneous audio webcast to discuss the fourth quarter and year end 2010 results at 8:30 a.m. ET today. The conference call can be accessed by dialing (877) 383-7419. The webcast can be accessed through the investor section of RTI’s website at www.rtix.com. A replay of the webcast will be available on the RTI website following the call.

Use of Non-GAAP Financial Measures

A reconciliation of the company’s non-GAAP financial measures to the corresponding GAAP measures, and an explanation of the company’s use of the non-GAAP measures, is included in the exhibits to this press release.

About RTI Biologics Inc.

RTI Biologics Inc. is a leading provider of sterile biologic implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening and using proprietary processes. These allograft and xenograft implants are used in orthopedic, dental and other specialty surgeries.

RTI’s innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. Two such processes – the BioCleanse® Tissue Sterilization Process and the Tutoplast® Tissue Sterilization Process – have a combined record of more than two million implants distributed with zero incidence of allograft-associated infection. These processes have been validated by tissue type to inactivate or remove viruses, bacteria, fungi and spores from the tissue while maintaining biocompatibility and functionality.

RTI’s worldwide corporate headquarters are located in Alachua, Fla., with international locations in Germany and France. The company is accredited by the American Association of Tissue Banks in the United States.

Forward Looking Statement

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company’s SEC filings may be obtained by contacting the company or the SEC or by visiting RTI’s website at www.rtix.com or the SEC’s website at www.sec.gov.
 

Use of Non-GAAP Financial Measures

To supplement RTI Biologics’ condensed consolidated financial statements presented on a GAAP basis, the company discloses certain non- GAAP financial measures that exclude certain amounts, including non-GAAP net income and non –GAAP impact per fully diluted share. These non-GAAP financial measures are not in accordance with, or an alternative for, generally accepted accounting principles in the United States. Reconciliations of non-GAAP financial measures to the corresponding GAAP measures are included in the reconciliation above.

The following is an explanation of the adjustment that management excluded as part of the non-GAAP measures for the year ended December 31, 2010 as well as the reason for excluding the individual item.

Goodwill impairment charge – This adjustment relates to evaluating the goodwill associated with the purchase of Tutogen Medical Inc. Management removes the impact of the goodwill impairment charge from the Company’s operating results to assist in assessing its operating performance in the current period and to supplement a comparison to the Company’s past operating performance.

Material Limitations Associated with the Use of Non-GAAP Financial Measures

Non-GAAP net income and non-GAAP impact per fully diluted share should not be considered in isolation, or as a replacement for GAAP measures.

Usefulness of Non-GAAP Financial Measures to Investors

The Company believes that presenting non-GAAP net income and non-GAAP impact per fully diluted share in addition to the related GAAP measures provide investors greater transparency to the information used by management in its financial decision-making which excludes the impairment charges. The Company further believes that providing this information better enables RTI Biologics’ investors to understand the Company’s overall core performance and to evaluate the methodology used by management to assess and measure such performance.

RTI will host a conference call and simultaneous audio webcast to discuss the fourth quarter and year end 2010 results at 8:30 a.m. ET the same day. The conference call can be accessed by dialing (877) 383-7419. The webcast can be accessed through the investor section of RTI’s website at www.rtix.com. A replay of the conference call will be available on the RTI website for one month following the call.

About RTI Biologics Inc.

RTI Biologics Inc. is a leading provider of sterile biologic implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening, precision shaping and using proprietary, validated processes. These allograft and xenograft implants are used in orthopedic, dental and other specialty surgeries.

RTI’s innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. Two such processes – the BioCleanse® Tissue Sterilization Process and the Tutoplast® Tissue Sterilization Process – have a combined record of more than two million implants distributed with zero incidence of allograft-associated infection. These processes have been validated by tissue type to inactivate or remove viruses, bacteria, fungi and spores from the tissue while maintaining biocompatibility and functionality.

RTI’s worldwide corporate headquarters are located in Alachua, Fla., with international locations in Germany and France. The company is accredited by the American Association of Tissue Banks in the United States.

Forward Looking Statement

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company’s SEC filings may be obtained by contacting the company or the SEC or by visiting RTI’s website at www.rtix.com or the SEC’s website at www.sec.gov.

###

Quarterly Highlights:

• Achieved quarterly revenues of $41.8 million, with gross margin of 48 percent.
• Achieved growth in the domestic sports medicine business of 20 percent over third quarter 2009.
• Signed an exclusive, 10-year distribution agreement with Zimmer Dental Inc. for biologic implants for the dental market worldwide.
• Signed an exclusive agreement with Athersys Inc. to provide RTI access to its Multipotent Adult Progenitor Cell (MAPC) technologies.
• Signed a distribution agreement with SeaSpine, a new distributor for spinal implants, and launched a new cervical construct.
• Launched a new spine implant with Medtronic.
• Net loss of $133.1 million, or $2.43 per fully diluted share, included a non-cash goodwill impairment charge.
• Adjusted net income, excluding the impairment charge, was $1.6 million, or $0.03 per fully diluted share.

“Revenues in the third quarter met expectations as our direct businesses, including sports medicine, demonstrated continued strength. In addition, we are pleased to have completed our revised distribution agreement with Zimmer and signed the licensing agreement with Athersys during the quarter,” said Brian K. Hutchison, chairman and CEO of RTI. “We remain confident that we will reach our financial goals for the rest of the year despite challenging conditions in some of our end markets.”

Revenues of $41.8 million for the third quarter of 2010 decreased 2 percent compared to the third quarter of 2009. Domestic revenues of $37.6 million for the third quarter increased 1 percent on the strength of the direct sports medicine business. International revenues of $4.2 million decreased 23 percent primarily due to economic weakness in several international markets. During the third quarter, currency exchange fluctuations resulted in a decrease in revenues of $376,000.

For the third quarter of 2010, the company reported a net loss of $133.1 million and a net loss per fully diluted share of $2.43 based on 54.8 million fully diluted shares outstanding, compared to net income of $2.3 million and net income per fully diluted share of $0.04 for the third quarter 2009, based on 55.0 million fully diluted shares outstanding.

Third quarter results include a decrease in income of $134.7 million, or $2.46 per fully diluted share, due to a non-cash goodwill impairment charge. The impairment charge is a result of an analysis of recorded goodwill in accordance with the financial accounting and reporting requirements of the Financial Accounting Standards Board ASC 350, Goodwill and Other Intangible Assets, considering the decline in the market value of the company’s equity during the third quarter.

2010 Outlook

The company reaffirmed previously issued 2010 fiscal guidance that full year revenues are estimated to be between $165 million and $168 million. Excluding the impact of the goodwill impairment charge taken in the third quarter, the full year earnings per fully diluted share are expected to be in the range of $0.10 to $0.12, based on 55.0 million fully diluted shares outstanding.

Conference Call

RTI will host a conference call and simultaneous audio webcast to discuss the third quarter results at 9:00 a.m. ET today. The conference call can be accessed by dialing (877) 383-7419. The webcast can be accessed through the investor section of RTI’s website at www.rtix.com. A telephone replay of the call will be available through Dec. 4, 2010 and can be accessed by calling (800) 642-1687, pass code 17891989; the replay will also be available at www.rtix.com.

Use of Non-GAAP Financial Measures

A reconciliation of the company’s non-GAAP financial measures to the corresponding GAAP measures, and an explanation of the company’s use of the non-GAAP measures, is included in the exhibits to this press release.

About RTI Biologics Inc.

RTI Biologics Inc. is a leading provider of sterile biologic implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening, precision shaping and using proprietary, validated processes. These allograft and xenograft implants are used in orthopedic, dental and other specialty surgeries.

RTI’s innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. Two such processes – the BioCleanse® Tissue Sterilization Process and the Tutoplast® Tissue Sterilization Process – have a combined record of more than two million implants distributed with zero incidence of allograft-associated infection. These processes have been validated by tissue type to inactivate or remove viruses, bacteria, fungi and spores from the tissue while maintaining biocompatibility and functionality.

RTI’s worldwide corporate headquarters are located in Alachua, Fla., with international locations in Germany and France. The company is accredited by the American Association of Tissue Banks in the United States.

Forward Looking Statement

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company’s SEC filings may be obtained by contacting the company or the SEC or by visiting RTI’s website at www.rtix.com or the SEC’s website at www.sec.gov.

Use of Non-GAAP Financial Measures

To supplement RTI Biologics’ condensed consolidated financial statements presented on a GAAP basis, the company discloses certain non- GAAP financial measures that exclude certain amounts, including non-GAAP net income and non –GAAP impact per fully diluted share. These non-GAAP financial measures are not in accordance with, or an alternative for, generally accepted accounting principles in the United States. Reconciliations of non-GAAP financial measures to the corresponding GAAP measures are included in the reconciliation above.

The following is an explanation of the adjustment that management excluded as part of the non-GAAP measures for the three and nine month periods ended September 30, 2010 as well as the reason for excluding the individual item.

Goodwill impairment charge – This adjustment relates to evaluating the goodwill associated with the purchase of Tutogen Medical Inc. Management removes the impact of the goodwill impairment charge from the Company’s operating results to assist in assessing its operating performance in the current period and to supplement a comparison to the Company’s past operating performance.

Material Limitations Associated with the Use of Non-GAAP Financial Measures

Non-GAAP net income and non-GAAP impact per fully diluted share should not be considered in isolation, or as a replacement for GAAP measures.

Usefulness of Non-GAAP Financial Measures to Investors

The Company believes that presenting non-GAAP net income and non-GAAP impact per fully diluted share in addition to the related GAAP measures provide investors greater transparency to the information used by management in its financial decision-making which excludes the impairment charges. The Company further believes that providing this information better enables RTI Biologics’ investors to understand the Company’s overall core performance and to evaluate the methodology used by management to assess and measure such performance.

ALACHUA, Fla. (Oct. 26, 2010) – RTI Biologics Inc. (RTI) (Nasdaq: RTIX), a leading provider of orthopedic and other biologic implants, announced today that it plans to release financial results from the third quarter 2010 on Thursday, Nov. 4, 2010 prior to the market open.

RTI will host a conference call and simultaneous audio webcast to discuss the third quarter results at 9:00 a.m. ET the same day. The conference call can be accessed by dialing (877) 383-7419. The webcast can be accessed through the investor section of RTI’s website at www.rtix.com. A telephone replay of the call will be available through Dec. 4, 2010 and can be accessed by calling (800) 642-1687, pass code 17891989; the replay will also be available at www.rtix.com.

2010 Analyst Day

RTI will host a meeting for analysts at the RTI Biologics headquarters, 11621 Research Circle, Alachua, Fla., on Friday, Nov. 12, 2010. Company presentations will run from 8:30 a.m. to 1:00 p.m. ET.

The agenda will include an overview of the company and markets it serves, an update on research and development initiatives, operations and financials, and a tour of the facility. Presenters will include:

• Brian Hutchison, Chairman and Chief Executive Officer
• Roger Rose, Executive Vice President and Chief Commercial Officer
• Tom Rose, Executive Vice President and Chief Operations Officer
• Carrie Hartill, Executive Vice President and Chief Scientific Officer
• Rob Jordheim, Executive Vice President and Chief Financial Officer

A live webcast of the meeting will be available online from the investor relations page of RTI’s website at www.rtix.com. A replay of the webcast will be available on the website for 30 days.

For more information or to register to attend the event, please contact Wendy Crites Wacker at wwacker@rtix.com.

About RTI Biologics Inc.

RTI Biologics Inc. is a leading provider of sterile biologic implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening, precision shaping and using proprietary, validated processes. These allograft and xenograft implants are used in orthopedic, dental and other specialty surgeries.

RTI’s innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. Two such processes – the BioCleanse® Tissue Sterilization Process and the Tutoplast® Tissue Sterilization Process – have a combined record of more than two million implants distributed with zero incidence of allograft-associated infection. These processes have been validated by tissue type to inactivate or remove viruses, bacteria, fungi and spores from the tissue while maintaining biocompatibility and functionality.

RTI’s worldwide corporate headquarters are located in Alachua, Fla., with international locations in Germany and France. The company is accredited by the American Association of Tissue Banks in the United States.

Forward Looking Statement

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company’s SEC filings may be obtained by contacting the company or the SEC or by visiting RTI’s website at www.rtix.com or the SEC’s website at www.sec.gov.

###